Alphamab Oncology To Publish Cancer Drug's Phase III Trial Results

MT Newswires Live09-09

Alphamab Oncology (HKG:9966) said it carried out Phase III clinical trials of its cancer drug KN046 and will publish results at industry conferences after sufficient data analysis, according to a Friday filing on the Hong Kong bourse.

The overall survival analysis showed that KN046, in combination with platinum-based chemotherapy, demonstrated statistically significant overall survival improvement compared with placebo in combination with platinum-based chemotherapy in patients with squamous non-small cell lung cancer.

The drugmaker added that there are no guarantees that the new drug application of KN046 will be accepted and approved by the regulatory authorities.

KN046 is a cancer treatment drug targeting the PD-L1/CTLA-4 bispecific antibody to improve localization with the tumor microenvironment and reduce off-target toxicity.

Price (HKD): $2.29, Change: $+0.010, Percent Change: +0.44%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466562311?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-09 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466562311","market":"sg","top_or_hot":-1,"title":"Alphamab Oncology To Publish Cancer Drug's Phase III Trial Results","media":"MT Newswires Live","content":"<html><body><p> Alphamab Oncology (HKG:9966) said it carried out Phase III clinical trials of its cancer drug KN046 and will publish results at industry conferences after sufficient data analysis, according to a Friday filing on the Hong Kong bourse.</p><p>The overall survival analysis showed that KN046, in combination with platinum-based chemotherapy, demonstrated statistically significant overall survival improvement compared with placebo in combination with platinum-based chemotherapy in patients with squamous non-small cell lung cancer.</p><p>The drugmaker added that there are no guarantees that the new drug application of KN046 will be accepted and approved by the regulatory authorities.</p><p>KN046 is a cancer treatment drug targeting the PD-L1/CTLA-4 bispecific antibody to improve localization with the tumor microenvironment and reduce off-target toxicity.</p><p>Price (HKD): $2.29, Change: $+0.010, Percent Change: +0.44%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alphamab Oncology To Publish Cancer Drug's Phase III Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlphamab Oncology To Publish Cancer Drug's Phase III Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-09 17:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alphamab Oncology (HKG:9966) said it carried out Phase III clinical trials of its cancer drug KN046 and will publish results at industry conferences after sufficient data analysis, according to a ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2466562311","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466562311","pubTimestamp":1725872599,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alphamab Oncology  said it carried out Phase III clinical trials of its cancer drug KN046 and will publish results at industry conferences after sufficient data analysis, according to a Friday filing on the Hong Kong bourse.The overall survival analysis showed that KN046, in combination with platinum-based chemotherapy, demonstrated statistically significant overall survival improvement compared with placebo in combination with platinum-based chemotherapy in patients with squamous non-small cell lung cancer.The drugmaker added that there are no guarantees that the new drug application of KN046 will be accepted and approved by the regulatory authorities.KN046 is a cancer treatment drug targeting the PD-L1/CTLA-4 bispecific antibody to improve localization with the tumor microenvironment and reduce off-target toxicity.Price : $2.29, Change: $+0.010, Percent Change: +0.44%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK1574":"生物医药B类股","III":"信息服务","BK4588":"碎股","BK4526":"热门中概股","HKD":"尚乘数科","BK4023":"应用软件","09966":"康宁杰瑞制药-B","BK4134":"信息科技咨询与其它服务"},"translate_title":"康宁杰瑞肿瘤将公布癌症药物III期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"III":1,"09966":0.9},"content_text":"Alphamab Oncology (HKG:9966) said it carried out Phase III clinical trials of its cancer drug KN046 and will publish results at industry conferences after sufficient data analysis, according to a Friday filing on the Hong Kong bourse.The overall survival analysis showed that KN046, in combination with platinum-based chemotherapy, demonstrated statistically significant overall survival improvement compared with placebo in combination with platinum-based chemotherapy in patients with squamous non-small cell lung cancer.The drugmaker added that there are no guarantees that the new drug application of KN046 will be accepted and approved by the regulatory authorities.KN046 is a cancer treatment drug targeting the PD-L1/CTLA-4 bispecific antibody to improve localization with the tumor microenvironment and reduce off-target toxicity.Price (HKD): $2.29, Change: $+0.010, Percent Change: +0.44%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466562311"}